AdjuTec Pharma AS is a Norwegian pharmaceutical start-up company that was founded in 2019 based on research in antibiotic products at the University of Oslo (UoO), Norway.  

The company vision is to provide novel antibiotic resistance breakers to meet the imminent threat to modern medicine of antimicrobial resistance (AMR).

AdjuTec's core technology is synthesis of β-lactamase inhibitors (BLIs) that inactivates bacteria resistance enzymes. By taking down bacteria defense we are able to preserve susceptibility of broad-spectrum antibiotics.

Supported by national and EU-grants as well as private funding, AdjuTec will start clinical development of its lead product APC148 in September 2024.

AdjuTec Pharma AS

Org chart

Teams

Offices

AdjuTec Pharma AS

Org chart

Teams

Offices

Related companies